Through bioassay-guided fractionation, thirteen compounds (1-13) were isolated from the dry root of Semiaquilegia adoxoides, known as Tiankuizi in traditional Chinese medicine (TCM). Among these, four benzoic acid derivatives (1, 2, 4, 5), one 4,6-dimethoxy-5-methyl-2H-pyran-2-one (10) and one 1,2,3-propanetriol (13) were found for the first time in S. adoxoides. This is the first record of compound 10 from a natural source. 4-Hydroxybenzoic acid (1) and 3,4-dihyroxybenzoic acid (2) showed selective inhibition against elastase release and superoxide anion generation, with IC 50 values of 3.20 and 6.21 μg/mL, respectively. Compound 1 had 7-fold better activity than the positive control against elastase release induced by human neutrophils. Overall, our studies demonstrated Tiankuizi (S. adoxoides) as a potential TCM and isolates 1 and 2 as promising lead compounds for neutrophilic inflammatory diseases.
Semiaquilegia adoxoides (DC.) Makino, family Ranunculaceae, distributed mainly in mainland China, Japan and Korea, is the only species in the genus Semiaquilegia. The dry roots of this plant, called Tiankuizi in traditional Chinese medicine (TCM), have been used for their anti-inflammatory, anti-neoplastic, and antibacterial activities, and for the treatment of snakebite in folk medicine [1] [2] [3] [4] [5] [6] . Thirty compounds have been reported from S. adoxoides to date, including six cyano-compounds [1, 6, 7] , three alkaloids [1, 4, 8] , three benzoic acid derivatives [4, 8] , three benzofuranones [1, 7] , three diterpenes [5, 6] , three steroids [1, 2] , three fatty acids [8] , two simple benzene derivatives [8] , one nitro-compound [2] , one flavonoid [1] , one amide [9] and one furan [9] . However, it is interesting that the bioactive constituents from this plant have not been evaluated in a systematic manner.
Tiankuizi, especially, is often included in many multiple TCM formulas to cure cancer patients. In our preliminary study, a MeOH extract of Tiankuizi was separated into EtOAc-, n-BuOH-and water-soluble fractions, respectively. The three extracts were screened for cytotoxic activity against human lung (A549, H1299), breast (MDA-MB-231), ovarian (SKOV3), colon (HCT116, HT29), pancreas (AsPC-1) and oral (Ca922) cancer cell lines. All were inactive, with IC 50 values of > 100 μg/mL. However, during the course of an anti-neutrophilic inflammatory screening program on natural products, it was found that the EtOAc-and n-BuOH-extracts of Tiankuizi were active against superoxide anion generation and elastase release induced by human neutrophils. Respiratory system diseases always have the severe problem of mucus hypersecretion, in which superoxide anion and elastase are produced in large amounts by activated neutrophils. In such a situation, neutrophil inflammation will lead to deterioration of the disease and a high mortality rate. Therefore, finding potential new drugs to treat neutrophilic inflammatory diseases has become a necessity. Therefore, the TCM, Tiankuizi, was first selected as a lead to be investigated for anti-neutrophilic inflammatory activity through bioassay-guided fractionation.
A MeOH extract of Tiankuizi was partitioned between EtOAc-H 2 O (1:1), and then the aqueous layer between n-BuOH and H 2 O (1:1) to obtain EtOAc (SAE), n-BuOH (SAB) and water (SAW) fractions, respectively. As shown in Table 1 , the EtOAc-and n-BuOH-soluble fractions possessed inhibitory effects of 84.8% and 54.4% against superoxide anion generation, respectively at the concentration of 10 μg/mL. In addition, only the EtOAc-soluble fraction produced significant inhibition of elastase release. Fractionation of the EtOAc and n-BuOH extracts led to the isolation of thirteen compounds, including five benzoic acid derivatives, 4-hydroxybenzoic acid (1), 3,4-dihyroxybenzoic acid (2), 3-methoxy-4-hydroxybenzoic acid (3), p-β-D-glucosyloxybenzoic acid (4) [10] , monordicophenoide A (5) [11] , three alkaloids, thalifendine (6) [8] , magnoflorine (7) [1] , [12, 13] , one benzofuranone, griffonilide (11) [1] , sitosterol-3-β-D-glucose (12) [1] , and 1,2,3-propanetriol (13) . All structures were identified by NMR spectroscopic and MS data interpretation. 1 H, 13 C and HSQC NMR spectra of compound 10 indicated three singlet methyl groups (δ H 2.32/δ C 14.9, δ H 3.76/δ C 56.8 and δ H 3.86/δ C 60.2) and one olefinic proton (δ H 7.49, s/δ C 136.9). In the 13 C NMR spectrum, there are four quaternary carbons (144.3, 148.8, 158.5, 170.4) in addition. As Figure 1 shows, the HMBC and NOESY spectra suggested the structure of 10 as 2H-pyran-2-one, 4,6-dimethoxy-5-methyl. This was synthesized in 1989 by Venkataraman and Cha [12, 13] , but clear spectral data and biological properties of 10 were never reported. Compound 10 is reported by us for the first time as a naturally occurring substance.
Of the thirteen compounds isolated from Tiankuizi, the four benzoic acid derivatives (1, 2, 4, 5), and compounds 10 and 13 are reported for the first time for S. adoxoides. Although, the crude extracts of Tiankuizi did not have cytotoxicity, all isolates were tested for cytotoxicity toward eight human cancer cell lines (A549, H1299, MDA-MB-231, SKOV3, HCT116, HT29, AsPC-1 and Ca922), but all were inactive, with IC 50 values of > 100 μg/mL.
All the isolates, excluding 10, were tested in the anti-neutrophilic inflammation assay based on their effects against superoxide anion generation and elastase release by human neutrophils in response to formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP)/cytochalasin B (CB) ( Table 2 ). Diphenyleneiodonium (DPI) and phenylmethylsulfonyl fluoride (PMSF) were used as the positive controls, respectively. Compounds 1 and 2 showed selective inhibition against elastase release and superoxide anion generation with IC 50 values of 3.2 and 6.2 μg/mL, respectively. Compound 1 had a 7-fold better activity than the positive control, PMSF, against elastase release by human neutrophils. Among the benzoic acid derivatives 1-5, the main differences in their structures are the para-(OH, glucopyranosyl, furanosyl-glucopyranosyl) and meta-substituents (H, OH, OMe). The data for compounds 1, 4, and 5 in Table 2 , suggest that the free OH para-substituent of benzoic acid is more favorable. In addition, the potency of a meta-substituent H or OH is better than that of OMe among the p-hydroxy benzoic acids 1-3.
The alkaloids and other compounds showed no anti-neutrophilic inflammatory property. Overall, our studies indicated Tiankuizi (S. adoxoides) as a potential natural source and 4-hydroxybenzoic acid (1) and 3,4-dihyroxybenzoic acid (2) as promising compounds for further study of neutrophilic inflammatory diseases, like asthma.
Experimental
General: 1D ( 1 H, 13 Extraction and isolation: Tiankuizi (260.5 g) was extracted 3 times with MeOH (700 mL each) at room temperature to obtain a crude extract. The MeOH extract (94.7 g) was partitioned between EtOAc and H 2 O (400 mL/400 mL, 5 times) to give an EtOAc-soluble fraction (4.4 g) and the aqueous phase (89.3 g), which was further partitioned with n-BuOH-H 2 O (500 mL/500 mL, 3 times) to give n-BuOH-(16.7 g) and H 2 O-soluble fractions (69.7 g).The EtOAcsoluble fraction (4.4 g) was subjected to open CC on silica gel (70-230 mesh, column: 5 × 19 cm), using gradients of n-hexane-CHCl 3 -MeOH to give 12 subfractions (SAE1~SAE12). Fraction SAE94 (27.6 mg) was further purified by preparative TLC to obtain 1 (2.4 mg). SAE9 (98.8 mg) was fractionated by Sephadex LH-20 CC (column diameter: 3 cm, length: 29 cm; CHCl 3 -MeOH, 1:1) to yield 5 fractions (SAE91~ SAE95). Subfraction SAE10 (872.9 mg) was divided into 5 fractions by silica gel CC (230-400 mesh, column: 2.5 × 25 cm) using gradients of CHCl 3 -MeOH (10:1; 8:1; 6:1; 4:1; 1:1). A precipitate, obtained from subfraction SAE103 (293.3 mg), using MeOH, afforded 12 (60.4 mg). The residue (232.9 mg) of SAE103 was subjected to Sephadex LH-20 CC (column diameter: 3 cm, length: 28.5 cm; CHCl 3 -MeOH, 1:1) to give 6 subfractions. Subfraction SAE1034 (109.7 mg) was chromatographed on a silica gel column (230-400 mesh, column: 2 × 26 cm), using EtOAc-MeOH (100:0; 50:1; 30:1; 5:1; 0:100). Subfraction SAE10344 (28.8 mg) was purified subsequently by preparative TLC with CHCl 3 -MeOH (10:1) to obtain 11 (10.5 mg) . Subfraction SAE1035 (39.8 mg) was purified by preparative TLC (CHCl 3 -MeOH, 8:1) to give 2 (8.5 mg). Fraction SAE7 (104.9 mg) was subjected to Sephadex LH-20 CC (column diameter: 3 cm, length: 28 cm; CHCl 3 -MeOH, 1:1) and subfraction SAE73 (47.9 mg) to preparative TLC (n-Hexane-EtOAc, 1:2) to give 3 (4.6 mg). Fraction SAE3 (48.2 mg) was purified by preparative TLC (n-Hexane-EtOAc, 1:1) to give 10 and silica chromatography (230-400 mesh, column: 2.5 × 27 cm; CHCl 3 -MeOH, 8:1; 6:1) to obtain 6 (8.0 mg). Fraction SAB2 (1.4 g) was separated into 7 subfractions by CC on silica gel (column: 2.5 × 25 cm; EtOAc-MeOH, 5:1). Subfraction SAB22 (168.0 mg) was subjected to silica gel chromatography (230-400 mesh, column: 2 × 25 cm; EtOAc-MeOH, 100:0; 10:1; 5:1; 1:1; 0:100) and subfraction SAB229 (30.9 mg) was further purified by preparative TLC (CHCl 3 -MeOH, 3:1) to give 4 (11.6 mg). Fraction SAB23 (235.0 mg) was purified by Sephadex LH-20 (column diameter: 3 cm, length: 24 cm; MeOH) and silica gel CC (230-400 mesh, column: 2 × 22 cm; CHCl 3 -MeOH, 3:1) to give 5 (18.7 mg). Compound 8 (3.9 mg) was precipitated and purified from subfraction SAB24 (120.0 mg) using MeOH. Fraction SAB27 (106.0 mg) was divided by RP-18 CC (column: 2.5 × 28 cm; MeOH-H 2 O, 80:20) into 7 fractions (56.0 mg). Subfraction SAB3 (413.0 mg) was separated by silica gel (230-400 mesh, column: 2.5 × 7 cm; CHCl 3 -MeOH, 8:1; 1:1; 0:1) and Sephadex LH-20 CC (column diameter: 2.5 cm, length: 26 cm; MeOH) to give subfraction SAB313 (69.7 mg), which was further purified by preparative TLC (CHCl 3 -MeOH, 3:1; EtOAc-MeOH, 4:1) to give 9 (10.9 mg). Cytotoxicity: Compounds were tested against human lung (A549, H1299), breast (MDA-MB-231), ovarian (SKOV3), colon (HCT116, HT29), pancreas (AsPC-1) and oral (Ca922) cancer cell lines using an established colorimetric MTT assay protocol [14] . The absorbance was measured at 550 nm using a microplate reader. The IC 50 is the concentration of agent that reduced cell viability by 50% under the experimental conditions.
4,6-dimethoxy-5-methyl-2H-Pyran

Measurement of superoxide anion generation:
The assay of the generation of superoxide anions was carried out according to established protocols by monitoring the reduction of ferricytochrome c that could be inhibited by superoxide dismutase [15] . N-Formyl-Met-Leu-Phe (FMLP, 100 nM)/cytochalasin B (CB, 1 µg/mL) was used as a stimulant to activate neutrophils to produce superoxide anions. The positive control was diphenyleneiodonium (DPI), which is a NADPH oxidase inhibitor.
Elastase release assays: Elastase release was measured by degranulation of azurophilic granules, as described previously [15] . Neutrophils were activated by 100 nM FMLP and 0.5 µg/mL CB to release elastase. Phenylmethylsulfonyl fluoride (PMSF), a serine protease inhibitor, was used as the positive control.
